Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
Interventions
Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (Lete-Cel (GSK3377794)), Cyclophosphamide, Fludarabine
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Malignant Peripheral Nerve Sheath Tumor, Locally Advanced Myxofibrosarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Epithelioid Sarcoma, Metastatic Fibrosarcoma, Metastatic Liposarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Myxofibrosarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Undifferentiated (Embryonal) Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Soft Tissue Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Malignant Adult Hemangiopericytoma, Malignant Childhood Hemangiopericytoma, Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Recurrent Dedifferentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
Interventions
Etrumadenant, Zimberelimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
651
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Neoplasms
Interventions
GSK3901961, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Liposarcoma
Interventions
efatutazone
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
127
States / cities
Little Rock, Arkansas • Aurora, Colorado • New Haven, Connecticut + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
nelfinavir mesylate, biopsy, laboratory biomarker analysis, pharmacological study, gene expression analysis, western blotting, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
10 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma
Interventions
pazopanib
Drug
Lead sponsor
Vector Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Post Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification, Myxoid Liposarcoma, CIC-Rearranged Sarcoma
Interventions
BTX-A51
Drug
Lead sponsor
Michael Wagner, MD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Myxoid Liposarcoma, Round Cell Liposarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Interventions
Biopsy, Laboratory Biomarker Analysis, Trabectedin
Procedure · Other · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Leiomyosarcoma
Interventions
Ontorpacept (TTI-621), Doxorubicin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Santa Monica, California • Jacksonville, Florida • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Neoplasms
Interventions
GSK3845097, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
241
States / cities
Phoenix, Arizona • Tucson, Arizona • Dublin, California + 196 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Liposarcoma, Metastatic Liposarcoma
Interventions
MGCD516
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma
Interventions
Sunitinib Malate (SU011248)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2012 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Interventions
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
Interventions
Avelumab, Trabectedin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced May 21, 2026, 6:18 PM EDT